| Type | Title | Date Released | |
|---|---|---|---|
8-K | Oncolytics Biotech Announces Translational Data for Pelareorep in Multiple Myeloma at the ASH Annual Meeting New | ||
8-K | Translational Data Show Oncolytics' Pelareorep Drives HPV-Specific Immune Responses in Anal Cancer Patients | ||
8-K | Oncolytics Biotech Reports Positive Durability and Survival Data for Pelareorep in Anal Cancer and Outlines HPV-Driven Cancer Expansion Strategy | ||
8-K | Oncolytics Biotech Presenting REO 033 Trial in Progress Abstract at ESMO for Pelareorep in Colorectal Cancer | ||
8-K | Oncolytics Biotech Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment | ||
8-K | Oncolytics Biotech Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update | ||
DEFA14A | Form DEFA14A | ||
DEF 14A | Form DEF 14A | ||
8-K | Oncolytics Biotech Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer | ||
8-K | Oncolytics Biotech Reports Accelerating Enrollment and Site Activations in Randomized REO 033 Colorectal Cancer Study | ||
8-K | Oncolytics Biotech Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer | ||
8-K | Oncolytics Biotech Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer |
